{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T15:28:26Z","timestamp":1778858906707,"version":"3.51.4"},"reference-count":29,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T00:00:00Z","timestamp":1725408000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>This article reviews the published data including the pharmacology, efficacy, and safety of aprocitentan, a novel endothelin receptor antagonist developed to treat hypertension in conjunction with additional agents.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data sources:<\/jats:title>\n                    <jats:p>A literature search was conducted from drug discovery until May 2024 through PubMed, MEDLINE, and National Institutes of Health Clinical Trials Registry utilizing the following search terms: Tryvio, aprocitentan, hypertension, resistant hypertension, endothelin receptor antagonist, and ACT-132577.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study selection and data extraction:<\/jats:title>\n                    <jats:p>All relevant English-language studies, or studies that could be appropriately translated into English, containing the pharmacology, pharmacokinetics, safety, and efficacy of aprocitentan, were selected for review.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data synthesis:<\/jats:title>\n                    <jats:p>In the setting of resistant hypertension, aprocitentan has shown significant reductions in blood pressure in both medical office and 24-hour ambulatory settings at 4 weeks with a sustained effect at 40 weeks. Studies evaluating cardiovascular risk reduction have not been conducted at this time. Fluid retention and edema were the most frequent adverse events reported in clinical studies with aprocitentan. As a class, endothelin receptor antagonists may cause fetal harm; aprocitentan should be used with caution to avoid embryo-fetal toxicity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Relevance to patient care and clinical practice in comparison to existing drugs:<\/jats:title>\n                    <jats:p>Owing to the existent barriers for the treatment of resistant hypertension, aprocitentan presents itself as an effective option when added to traditional antihypertensives. This single-strength, once-daily regimen may serve as an appealing option to both patients and prescribers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Aprocitentan is a safe and effective medication for the treatment of hypertension when added to other pharmacological therapies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10600280241273218","type":"journal-article","created":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T18:10:38Z","timestamp":1725646238000},"page":"364-370","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":2,"title":["Pressing Update: Aprocitentan for the Treatment of Hypertension"],"prefix":"10.1177","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2157-9037","authenticated-orcid":false,"given":"Bradley","family":"Phillips","sequence":"first","affiliation":[{"name":"Department of Pharmacy Education and Practice, College of Pharmacy, University of Florida, Orlando, FL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0638-1214","authenticated-orcid":false,"given":"Angelina","family":"Vascimini","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Education and Practice, College of Pharmacy, University of Florida, Gainesville, FL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chardae","family":"Whitner","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Education and Practice, College of Pharmacy, University of Florida, Jacksonville, FL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5404-2906","authenticated-orcid":false,"given":"Erin","family":"St. Onge","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Education and Practice, College of Pharmacy, University of Florida, Orlando, FL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0860-2108","authenticated-orcid":false,"given":"Jessica","family":"Huston","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Education and Practice, College of Pharmacy, University of Florida, Jacksonville, FL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2024,9,4]]},"reference":[{"key":"bibr1-10600280241273218","doi-asserted-by":"publisher","DOI":"10.1161\/HYP.0000000000000084"},{"key":"bibr2-10600280241273218","unstructured":"Centers for Disease Control and Prevention. Facts about hypertension. Published July 6, 2023. Accessed April 22, 2024. https:\/\/www.cdc.gov\/high-blood-pressure\/?CDC_AAref_Val=https:\/\/www.cdc.gov\/bloodpressure\/facts.html"},{"key":"bibr3-10600280241273218","doi-asserted-by":"publisher","DOI":"10.1161\/HYP.0000000000000066"},{"key":"bibr4-10600280241273218","unstructured":"Million Hearts. Estimated hypertension prevalence, treatment, and control among U.S. adults. Published May 12, 2023. Accessed April 24, 2024. https:\/\/millionhearts.hhs.gov\/data-reports\/hypertension-prevalence.html"},{"key":"bibr5-10600280241273218","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.118.12191"},{"key":"bibr6-10600280241273218","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.111.030189"},{"key":"bibr7-10600280241273218","doi-asserted-by":"publisher","DOI":"10.1093\/eurjpc\/zwad066"},{"key":"bibr8-10600280241273218","unstructured":"Idorsia Pharmaceuticals. US FDA approves Idorsia\u2019s once-daily TRYVIO (aprocitentan)\u2014the first and only endothelin receptor antagonist for the treatment of high blood pressure not adequately controlled in combination with other antihypertensives. Published March 20, 2024. Accessed April 21, 2024. https:\/\/www.idorsia.com\/media\/news\/news-archive\/media-release-details?id=3195250"},{"key":"bibr9-10600280241273218","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.34.4.876"},{"key":"bibr10-10600280241273218","unstructured":"Tryvio package insert. Idorsia Pharmaceuticals US Inc.; March, 2024."},{"key":"bibr11-10600280241273218","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.977110"},{"key":"bibr12-10600280241273218","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.881"},{"key":"bibr13-10600280241273218","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-019-00837-x"},{"key":"bibr14-10600280241273218","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-22470-z"},{"key":"bibr15-10600280241273218","doi-asserted-by":"publisher","DOI":"10.1007\/s13318-019-00590-8"},{"key":"bibr16-10600280241273218","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.815"},{"key":"bibr17-10600280241273218","doi-asserted-by":"publisher","DOI":"10.1007\/s40119-021-00233-7"},{"key":"bibr18-10600280241273218","doi-asserted-by":"publisher","DOI":"10.1097\/FJC.0000000000001023"},{"key":"bibr19-10600280241273218","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.119.14504"},{"key":"bibr20-10600280241273218","doi-asserted-by":"publisher","DOI":"10.1097\/CRD.0000000000000591"},{"key":"bibr21-10600280241273218","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)02034-7"},{"key":"bibr22-10600280241273218","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.1093406"},{"key":"bibr23-10600280241273218","doi-asserted-by":"publisher","DOI":"10.1139\/cjpp-2022-0010"},{"key":"bibr24-10600280241273218","doi-asserted-by":"publisher","DOI":"10.1111\/jch.14686"},{"key":"bibr25-10600280241273218","unstructured":"Brett A. Aprocitentan, a newly approved drug resistant hypertension. NEJM Journal Watch. Published April 11, 2024. Accessed May 3, 2024. https:\/\/www.jwatch.org\/na57341\/2024\/04\/11\/aprocitentan-newly-approved-drug-resistant-hypertension"},{"key":"bibr26-10600280241273218","unstructured":"Bernknoph A. Aliskiren (Tekturna) for the treatment of hypertension. Am Fam Physician. 2007;76(8):1203-1204. Accessed August 12, 2024. https:\/\/www.aafp.org\/pubs\/afp\/issues\/2007\/1015\/p1203.html"},{"key":"bibr27-10600280241273218","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvad165"},{"key":"bibr28-10600280241273218","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00257-3"},{"key":"bibr29-10600280241273218","doi-asserted-by":"publisher","DOI":"10.1208\/aapsj080117"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280241273218","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10600280241273218","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280241273218","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:13:48Z","timestamp":1777374828000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10600280241273218"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,4]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["10.1177\/10600280241273218"],"URL":"https:\/\/doi.org\/10.1177\/10600280241273218","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,4]]}}}